

Accepted Manuscript

Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML *in vitro* and *in vivo*

Ulrike Tontsch-Grunt, Dorothea Rudolph, Irene Waizenegger, Anke Baum, Daniel Gerlach, Harald Engelhardt, Melanie Wurm, Fabio Savarese, Norbert Schweifer, Norbert Kraut

PII: S0304-3835(18)30151-4

DOI: [10.1016/j.canlet.2018.02.018](https://doi.org/10.1016/j.canlet.2018.02.018)


Reference: CAN 13768

To appear in: *Cancer Letters*

Received Date: 11 September 2017

Revised Date: 29 January 2018

Accepted Date: 11 February 2018



Please cite this article as: U. Tontsch-Grunt, D. Rudolph, I. Waizenegger, A. Baum, D. Gerlach, H. Engelhardt, M. Wurm, F. Savarese, N. Schweifer, N. Kraut, Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML *in vitro* and *in vivo*, *Cancer Letters* (2018), doi: 10.1016/j.canlet.2018.02.018.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Abstract

Interactions between a new potent Bromodomain and extraterminal domain (BET) inhibitor BI 894999 and the polo-like kinase (PLK) inhibitor volasertib were studied in acute myeloid leukemia cell lines *in vitro* and *in vivo*. We provide data for the distinct mechanisms of action of these two compounds with a potential utility in AML based on gene expression, cell cycle profile and modulation of PD biomarkers such as MYC and HEXIM1. In contrast to BI 894999, volasertib treatment neither affects MYC nor HEXIM1 expression, but augments and prolongs the decrease of MYC expression caused by BI 894999 treatment. *In vitro* combination of both compounds leads to a decrease in S-Phase and to increased apoptosis. *In vitro* scheduling experiments guided *in vivo* experiments in disseminated AML mouse models. Co-administration of BI 894999 and volasertib dramatically reduces tumor burden accompanied by long-term survival of tumor-bearing mice and eradication of AML cells in mouse bone marrow.

Together, these preclinical findings provide evidence for the strong synergistic effect of BI 894999 and volasertib, warranting future clinical studies in patients with AML to investigate this paradigm.

Download English Version:

<https://daneshyari.com/en/article/8434626>

Download Persian Version:

<https://daneshyari.com/article/8434626>

[Daneshyari.com](https://daneshyari.com)